ciglitazone has been researched along with Hormone-Dependent Neoplasms in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moss, PE | 1 |
| Lyles, BE | 1 |
| Stewart, LV | 1 |
1 other study available for ciglitazone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
The PPARĪ³ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
Topics: Androgen-Binding Protein; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dihydrotestosterone; Gene | 2010 |